Historique
Article de Périodique
Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts (2012)
Auteur(s) :
MANRIQUE-GARCIA, E. ;
ZAMMIT, S. ;
DALMAN, C. ;
HEMMINGSSON, T. ;
ALLEBECK, P.
Année
2012
Page(s) :
7 p.
Langue(s) :
Anglais
Refs biblio. :
33
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PSY (Psychopathologie / Psychopathology)
Thésaurus mots-clés
TROUBLE BIPOLAIRE
;
ETUDE LONGITUDINALE
;
SEXE MASCULIN
;
CANNABIS
;
DEPRESSION
;
PSYCHOSE
;
SCHIZOPHRENIE
Thésaurus géographique
SUEDE
Résumé :
FRANÇAIS :
Selon cette étude sur le long terme, portant sur 45 087 hommes suédois, aucun effet de la consommation de cannabis n'a pu être observée dans le développement d'une dépression. Mais, un risque accru de schizophrénie a été confirmé. Les sujets ayant réalisé l'étude ont fourni des informations sur leur consommation de cannabis depuis qu'ils avaient 18 ans jusqu'à 35 ans. [Résumé IACM]
BACKGROUND: While there is increasing evidence on the association between cannabis use and psychotic outcomes, it is still unclear whether this also applies to depression. We aim to assess whether risk of depression and other affective outcomes is increased among cannabis users.
METHODS: A cohort study of 45 087 Swedish men with data on cannabis use at ages 18[EN DASH]20. Diagnoses of unipolar disorder, bipolar disorder, affective psychosis and schizoaffective disorder were identified from inpatient care records over a 35-year follow-up period. Cox proportional hazard modeling was used to assess the hazard ratio (HR) of developing these disorders in relation to cannabis exposure.
RESULTS: Only subjects with the highest level of cannabis use had an increased crude hazard ratio for depression (HR 1.5, 95% confidence interval (CI), 1.0-2.2), but the association disappeared after adjustment for confounders. There was a strong graded association between cannabis use and schizoaffective disorder, even after control for confounders, although the numbers were small (HR 7.4, 95% CI, 1.0-54.3).
CONCLUSION: We did not find evidence for an increased risk of depression among those who used cannabis. Our finding of an increased risk of schizoaffective disorder is consistent with previous findings on the relation between cannabis use and psychosis.
Selon cette étude sur le long terme, portant sur 45 087 hommes suédois, aucun effet de la consommation de cannabis n'a pu être observée dans le développement d'une dépression. Mais, un risque accru de schizophrénie a été confirmé. Les sujets ayant réalisé l'étude ont fourni des informations sur leur consommation de cannabis depuis qu'ils avaient 18 ans jusqu'à 35 ans. [Résumé IACM]
BACKGROUND: While there is increasing evidence on the association between cannabis use and psychotic outcomes, it is still unclear whether this also applies to depression. We aim to assess whether risk of depression and other affective outcomes is increased among cannabis users.
METHODS: A cohort study of 45 087 Swedish men with data on cannabis use at ages 18[EN DASH]20. Diagnoses of unipolar disorder, bipolar disorder, affective psychosis and schizoaffective disorder were identified from inpatient care records over a 35-year follow-up period. Cox proportional hazard modeling was used to assess the hazard ratio (HR) of developing these disorders in relation to cannabis exposure.
RESULTS: Only subjects with the highest level of cannabis use had an increased crude hazard ratio for depression (HR 1.5, 95% confidence interval (CI), 1.0-2.2), but the association disappeared after adjustment for confounders. There was a strong graded association between cannabis use and schizoaffective disorder, even after control for confounders, although the numbers were small (HR 7.4, 95% CI, 1.0-54.3).
CONCLUSION: We did not find evidence for an increased risk of depression among those who used cannabis. Our finding of an increased risk of schizoaffective disorder is consistent with previous findings on the relation between cannabis use and psychosis.
Affiliation :
Department of Public Health Sciences, Division of Social Medicine, Karolinska Institutet, Stockholm, Sweden